Amorchem
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Amorchem.
Key people at Amorchem.
Key people at Amorchem.
AmorChem is an early-stage venture capital fund based in Montreal, Canada, dedicated to creating the next generation of biotechnology companies by financing and supporting translational research originating primarily from academic institutions. Its mission is to bridge the innovation gap between fundamental academic discoveries and commercial biotech startups, focusing on developing groundbreaking therapeutic paradigms. AmorChem invests in life sciences projects at the seed stage, fostering a collaborative community of biotech entrepreneurs, academics, and investors to generate sustainable health and economic value[1][2][3][5].
Founded in 2011, AmorChem has financed over 30 research programs and helped launch several biotech companies, leveraging a unique venture model tailored to early-stage translational research. Key partners include general partners Dre Inès Holzbaur and Dre Elizabeth Douville, with principal limited partners such as Investissement-Québec, FIER Partenaires, Fonds de solidarité FTQ, and Merck & Co. The firm’s evolution has centered on deep scientific engagement and active community-building within Quebec’s life sciences ecosystem[1][3][6].
AmorChem rides the growing trend of translating academic biotech research into commercial ventures, addressing the critical innovation gap in life sciences. The timing is favorable due to increasing global investment in biotech, advances in therapeutic science, and a strong academic research base in Quebec. By focusing on early-stage projects, AmorChem helps catalyze innovation that might otherwise remain confined to academia, thus influencing the broader biotech ecosystem by nurturing a new generation of science entrepreneurs and companies[1][2][5].
Looking ahead, AmorChem is poised to continue expanding its portfolio and influence within the Canadian and global biotech sectors. Trends such as personalized medicine, advanced therapeutics, and AI-driven drug discovery will likely shape its investment focus. As the biotech ecosystem matures, AmorChem’s role as a bridge between academia and industry will become increasingly vital, potentially scaling its impact on health innovation and economic growth. Its collaborative community model and deep scientific expertise position it well to remain a premier early-stage biotech venture fund[1][5].
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 1, 2024 | Cardurion Pharmaceuticals | $260.0M Series B | — | Forbion, New Enterprise Associates |
| Mar 1, 2024 | Capstan Therapeutics | $180.0M Series B | — | Andera Partners, Earlybird Venture Capital, Forbion, Kurma Partners, Ed Mathers, Pfizer Venture Investments, Pureos Bioventures, Wellington Partners, Vincent Brichard |
| Oct 1, 2022 | Inversago Pharma | $69.0M Series C | — | Accel, Advent Life Sciences, Atlas Venture, Benchmark, Bond, Forbion, Longwood Fund, Matrix, Ed Mathers, New Enterprise Associates, Novartis Venture Fund, Soffinova Partners, Sofinnova Investments |
| Sep 1, 2020 | Inversago Pharma | $35.0M Series B | — | Atlas Venture, Forbion, Longwood Fund, Ed Mathers |
| Jul 1, 2018 | Inversago Pharma | $7.0M Series A | — | Forbion, Ed Mathers |
| Mar 1, 2015 | Thrasos | $21.0M Series D | — | Apollo Health Ventures, BDC Venture Capital |
| Sep 1, 2010 | Alethia BioTherapeutics | $9.0M Series A | — | BDC Venture Capital |
